Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. IV-HCC: Clinical and prognostic implications of plasma IGF-1 and VEGF in patients with hepatocellular carcinoma A O Kaseb 2011 ASCO Gastrointestinal Cancers Symposium. January, 2011
2. IV-HCC: Clinical and prognostic implications of plasma IGF-1 and VEGF in patients with hepatocellular carcinoma. 2011 ASCO Gastrointestinal Cancers Symposium January, 2011
3. Effect of incorporating plasma VEGF level into a V-CLIP scoring system on stratification of patients with hepatocellular carcinoma. A O Kaseb 2010 ASCO Gastrointestinal Cancers Symposium January, 2010
4. Prognostic effect of insulin growth factor-1 in hepatocellular carcinoma Adnan Siddiqui. 2010 ASCO Gastrointestinal Cancers Symposium. January, 2010
5. Retrospective analyses of 52 patients with fibrolamellar hepatocellular carcinoma: Treatment outcome and prognostic indicators. M Shama. 2010 ASCO Gastrointestinal Cancers Symposium January, 2010
6. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study A O Kaseb 2010 ASCO Annual Meeting January, 2010
7. Targeted Therapy for Hepatocellular carcinoma and bile ducts cancer (2 Lectures) Gastro-intestinal Cancer Meeting. September, 2009
8. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma. 2009 International Liver Cancer Association (ILCA) Annual Meeting January, 2009
9. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma 2009 ASCO Annual Meeting January, 2009
10. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma A. O. Kaseb 2009 ASCO Annual Meeting January, 2009
11. A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer N. Hammad 2008 ASCO Annual Meeting   January, 2008
12. Enhanced chemosensitivity to gemcitabine and oxaliplatin by thymoquinone in pancreatic cancer. A. O. Kaseb 2008 ASCO Annual Meeting   January, 2008
13. A phase II study of isoflavone (Novasoy), gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer N. Hammad 2008 Gastrointestinal Cancers Symposium January, 2008
14. A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma. A. O. Kaseb 2007 ASCO Annual Meeting January, 2007
15. A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma. 2007 ASCO Annual Meeting January, 2007
16. A 10-year retrospective analysis of risk factors and patterns of cancer recurrence post liver transplant (LT) for cirrhosis and hepatocellular carcinoma (HCC) 2007 Gastrointestinal Cancers Symposium January, 2007
17. A 10-year retrospective analysis of risk factors and patterns of cancer recurrence post liver transplant (LT) for cirrhosis and hepatocellular carcinoma (HCC). A. O. Kaseb 2007 Gastrointestinal Cancers Symposium January, 2007
18. Thymoquinone, a component of the herb Nigella sativa, suppresses proliferation and viability of prostate cancer cells by down-regulating androgen receptor and E2F-1. A. O. Kaseb 2006 Prostate Cancer Symposium January, 2006
19. Thymoquinone, a component of the herb Nigella sativa, suppresses proliferation and viability of prostate cancer cells by down-regulating androgen receptor and E2F-1. 2006 Prostate Cancer Symposium January, 2006
20. Thymoquinone, a component of the herb Nigella sativa, suppresses proliferation and viability of prostate cancer cells by down-regulating E2F-1 and androgen receptor 2006 ASCO Prostate Cancer Symposium, January, 2006
21. Thymoquinone, a component of the herb Nigella sativa, suppresses proliferation and viability of prostate cancer cells by down-regulating androgen receptor and E2F-1. A. O. Kaseb 2006 ASCO Annual Meeting January, 2006
22. Nephrin RT-QPCR of urinary sediment is a potential marker for occurrence and response to treatment of diabetic nephropathy 2005 National American College of Physicians (ACP) Meeting, January, 2005
23. Human Papilloma Virus (HPV-16) as a surrogate marker for Schistosomiasis-Induced Bladder Cancer. A. O. Kaseb 2005 ASCO Annual Meeting January, 2005
24. The relationship between HPV-16 infection and schistosomiasis-associated bladder cancer 2004 National American College of Physicians (ACP) Meeting January, 2004



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Where Do We Go Next? Top 5 Future Clinical Trials in Hepatocellular Carcinoma 2011 AHPBA Americas Post Graduate Course June, 2011

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.